Surpassing 4,000 confirmed cases, the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo has become the world’s second-largest on record. According to the Ministry of Health, health authorities are racing to contain the fastest-spreading epidemic of its kind while World Health Organization vaccine experts recommend full-scale human trials of the Ervebo vaccine for cross-protection against the untargeted strain.
Ministry of Health Confirms 4,053 Cases Across Five Provinces
The Democratic Republic of the Congo’s Ministry of Health reports that the national case count has reached 4,053, which includes 1,850 deaths since the epidemic was officially declared in mid-May. According to government data, the outbreak spans 53 health zones across five distinct provinces: Ituri, North Kivu, South Kivu, Haut-Uele, and Tshopo.
Ituri province remains the primary epicenter, capturing 87 percent of all recorded infections. Neighboring North Kivu accounts for another 11 percent of cases. Health officials note that ongoing military conflict, delayed detection, and a shortage of readily available treatments continue to hamper response efforts against the virus, which spreads through direct contact with bodily fluids.
WHO Recommends Ervebo Vaccine Trials for Cross-Protection
To combat the rare Bundibugyo strain—for which no dedicated vaccine currently exists—World Health Organization experts recommended prioritizing the licensed Ervebo vaccine for a randomized clinical trial. While Ervebo is proven safe and effective against the more common Zaire strain, preliminary data suggests it may offer vital cross-protection.
According to WHO findings, three out of four non-human primates vaccinated with Ervebo survived exposure to the Bundibugyo strain during animal studies, compared to just one out of four in control groups. Furthermore, an unpublished study on ferrets demonstrated that a research-grade version of Ervebo provided complete protection against the strain, whereas all control animals died within 10 days.
Did you know?
The Gavi global vaccine alliance maintains a stockpile of 500,000 Ervebo doses. Sania Nishtar confirmed that doses from this stockpile were to be made available for the trials, with some already in the DRC.
Comparing Historical Outbreaks and Vaccine Development Hurdles
Public health experts categorize the current situation in the DRC as the fastest-spreading Ebola epidemic on record. In terms of scale, it trails only the monumental 2014-2016 West Africa outbreak, which recorded more than 28,000 cases across Guinea, Liberia, and Sierra Leone.
Despite the promise of repurposing Ervebo, the United Nations’ Technical Advisory Group on Candidate Vaccine Prioritization (TAG-CVP) emphasizes that a strain-specific vaccine remains the ultimate goal. The advisory group cautions that expectations must be managed regarding Ervebo’s efficacy in a Phase III ring vaccination trial, noting it may achieve high protection against fatal outcomes rather than completely blocking symptomatic disease or transmission. Meanwhile, two potential Bundibugyo-specific vaccines are moving through early-stage human clinical trials.
Frequently Asked Questions
How many cases of the Bundibugyo strain have been reported in the DRC?
According to the Ministry of Health situation report, the DRC has recorded 4,053 cases and 1,850 deaths since mid-May.
Is there an approved vaccine for the Bundibugyo strain?
No dedicated vaccine exists for the Bundibugyo strain yet, though two candidate vaccines are currently in early-stage human clinical trials.
Why is the WHO recommending Ervebo?
The WHO recommends randomized trials of Ervebo—the only licensed Ebola vaccine for the Zaire strain—because animal studies indicate it may provide crucial cross-protection against the Bundibugyo strain.
Which province is hardest hit by the epidemic?
Ituri province is the epicenter of the outbreak, accounting for 87 percent of all confirmed cases across five affected provinces.
Stay Informed on Global Health Developments
Subscribe to our newsletter for verified updates on international public health emergencies, vaccine trials, and outbreak responses.
Related reading